SAMD9 and neoplasm: SAMD9-positive tumor cells localize to peri-necrotic and hypervascular niches, actively engaging with TAMs and vascular cells, and their expression predicts poor survival and resistance to anti-angiogenic and anti-PD-1 therapies.